Current companies developing γδ T cell-based immunotherapies

Companyγδ T cell typeAllogeneic vs. autologousTargeting strategy/engineering
GammaCell BiotechnologiesVδ2Autologous/allogeneicUnmodified
Hebei Senlang BiotechnologyVδ2AutologousCAR/αβTCR
Incysus TherapeuticsVδ2AutologousEngineered for chemo-resistance
Adicet Bio, Inc.Vδ1AllogeneicCAR
Beijing Doing BiomedicalVδ2AllogeneicUnmodified/CAR
Cytomed TherapeuticsVδ2AllogeneicCAR
GammaDelta TherapeuticsVδ1AllogeneicCAR
ImmaticsVδ2AllogeneicαβTCR
PhosphoGam Inc.Vδ2AllogeneicUnmodified
TC BioPharmVδ1/Vδ2Autologous/allogeneicUnmodified/CAR
Imcheck TherapeuticsVδ2Autologous (in vivo)Vδ2 activation with BTN3A
Lava TherapeuticsVδ2Autologous (in vivo)Activated Vδ2 with BiTE
PersonGen BioTherapeuticsγδ TAllogeneicTAA3-UCAR, CD7 UCAR
Expression TherapeuticsVδ2AllogeneicUnmodified/CAR

UCAR: universal CAR

Note. Adapted from "Cancer immunotherapy with γδ T cells: many paths ahead of us", by Kabelitz D, Serrano R, Kouakanou L, Peters C, Kalyan S. Cell Mol Immunol. 2020;17:925–39 (https://www.nature.com/articles/s41423-020-0504-x). CC-BY.